Physician profile
Niharika Yedla
NPI 1245785047
$3,637.75
in general payments reported to CMS, 2019-2025
22 companies · $901 in 2025
The $901 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $180 · 2021: $239 · 2022: $666 · 2023: $770 · 2024: $881 · 2025: $901.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,542 · Education: $11.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,541.71 |
| Education | $11.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $770.26 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $466.00 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Corcept Therapeutics | $374.95 | 2021-2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $230.75 | 2021-2025 | Farxiga |
| Xeris Pharmaceuticals, INC. | $223.56 | 2022-2025 | Recorlev, Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $213.28 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $179.15 | 2021-2023 | |
| Insulet Corporation | $162.01 | 2022-2025 | Omnipod |
| Astellas Pharma US INC | $156.02 | 2019 | |
| Radius Health, INC. | $139.00 | 2024-2025 | Tymlos |
| Amgen INC. | $132.32 | 2021-2025 | Prolia, Evenity, Tepezza |
| Tandem Diabetes Care, INC. | $126.45 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.29 | 2022-2025 | Jardiance, Tradjenta |
| Recordati_rare_diseases_inc. | $93.16 | 2025 | Isturisa |
| Dexcom, INC. | $65.68 | 2021-2023 | Dexcom G6 Transmitter |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $53.10 | 2024-2025 | |
| Amarin Pharma, INC. | $34.16 | 2022 | |
| Sequel Med Tech, LLC | $31.61 | 2025 | Twiist |
| Welch Allyn | $24.38 | 2021 | |
| Pfizer INC. | $24.11 | 2019 | |
| Esperion Therapeutics, INC. | $19.07 | 2025 | Nexletol |
| Optos, INC. | $17.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Niharika Yedla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.